148 related articles for article (PubMed ID: 37395971)
21. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
[TBL] [Abstract][Full Text] [Related]
22. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
23. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
[TBL] [Abstract][Full Text] [Related]
24. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.
Keyel ME; Reynolds CP
Biologics; 2019; 13():1-12. PubMed ID: 30613134
[TBL] [Abstract][Full Text] [Related]
25. Dinutuximab: first global approval.
Dhillon S
Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
[TBL] [Abstract][Full Text] [Related]
26. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
[TBL] [Abstract][Full Text] [Related]
27. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
28. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance.
Barone G; Barry A; Bautista F; Brichard B; Defachelles AS; Herd F; Manzitti C; Reinhardt D; Rubio PM; Wieczorek A; van Noesel MM
Paediatr Drugs; 2021 Nov; 23(6):537-548. PubMed ID: 34541620
[TBL] [Abstract][Full Text] [Related]
29. Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.
Ornell KJ; Taylor JS; Zeki J; Ikegaki N; Shimada H; Coburn JM; Chiu B
Cancer Med; 2020 Apr; 9(8):2891-2903. PubMed ID: 32096344
[TBL] [Abstract][Full Text] [Related]
30. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II clinical trial of high-dose [
Kuroda R; Wakabayashi H; Araki R; Inaki A; Nishimura R; Ikawa Y; Yoshimura K; Murayama T; Imai Y; Funasaka T; Wada T; Kinuya S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1574-1583. PubMed ID: 34837510
[TBL] [Abstract][Full Text] [Related]
32. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.
Secola R; Marachelian A; Cohn SL; Toy B; Neville K; Granger M; Brentlinger A; Martin G
J Pediatr Oncol Nurs; 2017; 34(3):160-172. PubMed ID: 28061552
[TBL] [Abstract][Full Text] [Related]
33. Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series.
Gartrell J; Shulkin BL; Helmig S; Caldwell KJ; Furman W; Federico SM
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e692-e696. PubMed ID: 33181583
[TBL] [Abstract][Full Text] [Related]
34. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
[TBL] [Abstract][Full Text] [Related]
35. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.
Barry WE; Jackson JR; Asuelime GE; Wu HW; Sun J; Wan Z; Malvar J; Sheard MA; Wang L; Seeger RC; Kim ES
Clin Cancer Res; 2019 Jan; 25(1):325-333. PubMed ID: 30232225
[TBL] [Abstract][Full Text] [Related]
36. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.
de Kraker J; Hoefnagel KA; Verschuur AC; van Eck B; van Santen HM; Caron HN
Eur J Cancer; 2008 Mar; 44(4):551-6. PubMed ID: 18267358
[TBL] [Abstract][Full Text] [Related]
37. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
38. Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma.
Launspach M; Seif M; Thole TM; Jesse P; Schulz J; Schulte JH; Bischoff S; Eggert A; Deubzer HE
Children (Basel); 2021 Jan; 8(2):. PubMed ID: 33572828
[TBL] [Abstract][Full Text] [Related]
39. Peripheral Stem Cell Apheresis is Feasible Post
Kraal KCJM; Timmerman I; Kansen HM; van den Bos C; Zsiros J; van den Berg H; Somers S; Braakman E; Peek AML; van Noesel MM; van der Schoot CE; Fiocco M; Caron HN; Voermans C; Tytgat GAM
Clin Cancer Res; 2019 Feb; 25(3):1012-1021. PubMed ID: 30314967
[TBL] [Abstract][Full Text] [Related]
40. Clinical implication of residual MIBG-positive disease in the follow-up of high-risk neuroblastoma treated with tandem high-dose chemotherapy and autologous stem cell transplantation.
Seo ES; Shin M; Lim H; Cho HW; Ju HY; Cho YS; Yoo KH; Koo HH; Lee JW; Sung KW
Pediatr Blood Cancer; 2022 Jul; 69(7):e29502. PubMed ID: 34889513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]